Premium
Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes
Author(s) -
Chaplin Steve,
Bain Stephen
Publication year - 2015
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1393
Subject(s) - dulaglutide , medicine , type 2 diabetes , exenatide , glucagon like peptide 1 receptor , agonist , diabetes mellitus , adverse effect , pharmacology , endocrinology , receptor
Dulaglutide is a once‐weekly GLP‐1 receptor agonist for the treatment of type 2 diabetes. Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Stephen Bain discusses its place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom